解读AMSTAR-2——基于随机和(或)非随机对照试验系统评价的质量评价工具

An Introduction of AMSTAR-2:A Quality Assessment Instrument of Systematic Reviews Including Randomized or Non-randomized Controlled Trials or Both

高质量的系统评价可以为临床医生、患者以及决策者提供有价值的信息。然而如何评价和识别高质量的系统评价,是证据使用者面临的一大难题。目前国际上存在诸多用于评价系统评价方法学质量的工具,主要以AMSTAR应用最为广泛。日前,更新版本的AMSTAR工具——AMSTAR-2在英国医学会期刊(BMJ)发表,主要更新框架包括:(1)采用PICO定义研究问题;(2)对原版本10个领域进行修改、细化和补充为12个领域,新增4个领域,AMSTAR-2由16个领域组成;(3)去除之前版本的"不适用"和"不能回答"两个选项,增加"部分符合"选项;(4)可以用于评价基于随机和/或非随机对照试验的系统评价;(5)推荐可能影响系统评价结果有效性的重要领域,并基于重要领域存在缺陷的程度评定系统评价的可信度。

Systematic reviews with high quality can provide valuable information for clinicians,patients,and decision markers.However , that, s really challenging for them to assess and identify systematic reviews with high quality. Currently , there are many in-ternational tool to assess the methodological quality of systematic reviews. Of them , AMSTAR instrument vised version （AMSTAR-2） has been published in BMJ. The major updated contents include：①Defining study questioPI CO.②AMSTAR-2 is consist of 16 domains , which 12 domains are from original revised version and 4are n ew .③Removing“ not applicable” and “ cannot answer” answer, andadding “ partial yes” answer.④Using to assess systematic reviews thatrandomised or non-randomised studies of healthcare interventions, or both;⑤Recommending the critical domains and rating the ccnfidence in the rsults of reviews.